Drug General Information |
Drug ID |
D0V0NJ
|
Former ID |
DNC012507
|
Drug Name |
2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C9H12N2
|
Canonical SMILES |
C1CNC2=CC=CC=C2CN1
|
InChI |
1S/C9H12N2/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10-11H,5-7H2
|
InChIKey |
MLXBHOCKBUILHN-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
Neuroactive ligand-receptor interaction
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Reactome
|
Adrenoceptors
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
G alpha (i) signalling events
|
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
|
Adrenaline,noradrenaline inhibits insulin secretion
|
G alpha (z) signalling events
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
Surfactant metabolism
|
WikiPathways
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Platelet Aggregation (Plug Formation)
|
GPCR ligand binding
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
Integration of energy metabolism
|
GPCR downstream signaling
|
References |
REF 1 | J Med Chem. 1996 Aug 30;39(18):3539-46.Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-methyltransferase. |